Advanced search
Publication Cover
Cancer Management and Research Volume 9, 2017 - Issue
Submit an article Journal homepage
251
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study

Umberto Restelli1 Center for Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Italy;2 School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
,
Giovanni Luca Ceresoli3 Medical Oncology Department, Thoracic and Urologic Oncology Unit, Cliniche Humanitas Gavazzeni, Bergamo
,
Davide Croce1 Center for Health Economics, Social and Health Care Management, LIUC – Università Cattaneo, Castellanza, Italy;2 School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
,
Laura Evangelista4 Nuclear Medicine and Molecular Imaging Unit, Veneto Institute of Oncology IOV – IRCCS, Padova
,
Lorenzo Stefano Maffioli5 Nuclear Medicine Department, Cancer Centre – ASST Ovest Milanese, Legnano
,
Letizia Gianoncelli3 Medical Oncology Department, Thoracic and Urologic Oncology Unit, Cliniche Humanitas Gavazzeni, Bergamo
&
Emilio Bombardieri6 Nuclear Medicine Department, Cliniche Humanitas Gavazzeni, Bergamo, ItalyCorrespondence[email protected]
 show all
Pages 789-800 | Published online: 07 Dec 2017

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Taro Iguchi, Yusuke Nakamura, Takeshi Akiyama, Krishant Chand & Eric Yu. (2022) Descriptive study on burden and communication of fatigue among castration-resistant prostate cancer patients in Japan. Current Medical Research and Opinion 38:3, pages 417-426.
Read now
Mohamad Moussa, Athanasios Papatsoris, Despoina Sryropoulou, Mohamed Abou Chakra, Athanasios Dellis & Lazaros Tzelves. (2021) A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. Expert Opinion on Pharmacotherapy 22:13, pages 1685-1728.
Read now
Alberto Bretoni, Lucrezia Ferrario & Emanuela Foglia. (2019) HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer. ClinicoEconomics and Outcomes Research 11, pages 283-300.
Read now
Yazan K. Barqawi, Matthew E. Borrego, Melissa H. Roberts & Ivo Abraham. (2019) Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance. Journal of Medical Economics 22:11, pages 1202-1209.
Read now
Hiroo Imai, Ken Saijo, Keigo Komine, Yoshifumi Kawamura, Sakura Hiraide, Sho Umegaki, Yoshinari Okada, Kota Ohuchi, Yuko Sato, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Masanobu Takahashi & Chikashi Ishioka. (2018) Predictive factors for the efficacy of the second taxane treatment in patients with advanced cancer. Cancer Management and Research 10, pages 3629-3636.
Read now

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.